Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease
Moebius, Hans J., Ooi, Kai‐Bin C., Hale, Michael D., Setti, Sharay E., Kleist, Kayla N., Pan, Josh, Church, Kevin J., Sabbagh, Marwan
Published in Alzheimer's & dementia (01.12.2023)
Published in Alzheimer's & dementia (01.12.2023)
Get full text
Journal Article